• The FDA has issued a Complete Response Letter (CRL) regarding Revance Therapeutics Inc's (NASDAQ: RVNC) marketing application for DaxibotulinumtoxinA for Injection for moderate to severe glabellar (frown) lines.

• The agency indicated deficiencies related to the FDA's onsite inspection at Revance's manufacturing facility.

• Revance plans to request a Type A meeting with the FDA to address the deficiencies raised. No other deficiencies were identified in the CRL.

• "We are very disappointed by this unanticipated response from the FDA and are seeking further clarity from the agency. We remain committed to bringing our next-generation neuromodulator product to market in both aesthetic and therapeutic indications," said Mark Foley, President and CEO.

• Related content: Benzinga's Full FDA Calendar.

• Price Action: RVNC shares are down 31.2% at $15.62 during the premarket session on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• Why Are Ocular Therapeutix Shares Trading Higher Today?

• Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.